GANX (Gain Therapeutics) Current Deferred Taxes Liabilities: $0.07 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GANX Gain Therapeutics Inc GANX
33 GF Score
Price $1.83
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Current Deferred Taxes Liabilities?

Gain Therapeutics GANX -4.45% 33 Current Deferred Taxes Liabilities is $0.07 Mil as of Jun. 2026. GuruFocus rates GANX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Gain Therapeutics's current deferred tax liabilities for the quarter that ended in Jun. 2026 was $0.07 Mil.

Gain Therapeutics Current Deferred Taxes Liabilities Related Terms

Gain Therapeutics Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics Current Deferred Taxes Liabilities Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial 0.00 0.11 0.05 0.02 0.04

Gain Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.05 0.04 0.07 0.07
GANX
33GF Score
Gain Therapeutics Inc GANX
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.07 Mil mean?
Gain Therapeutics (GANX) has a Current Deferred Taxes Liabilities of $0.07 Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Gain Therapeutics and its competitors.
Is Gain Therapeutics' Current Deferred Taxes Liabilities too high?
Gain Therapeutics' current Current Deferred Taxes Liabilities is $0.07 Mil. Overall, Gain Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' Current Deferred Taxes Liabilities compare to PYPD and MAIA?
Gain Therapeutics' Current Deferred Taxes Liabilities of $0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Gain Therapeutics and its competitors. Gain Therapeutics's current Current Deferred Taxes Liabilities is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current Current Deferred Taxes Liabilities of $0.07 Mil. The current Current Deferred Taxes Liabilities is $0.07 Mil. Gain Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current Current Deferred Taxes Liabilities is $0.07 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
33GF Score

Get the complete analysis for GANX

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.83
Price